Amsterdam, The Netherlands – 19 May 2019
Esperite N.V. (Euronext: ESP, “Esperite”) announces today that it has received a notice from Euronext that its ordinary shares will be transferred to trading group JG, a special segment for securities subject to listing measures. This listing measure was taken pursuant to article 6.9 of the Euronext Rule Book 1 due to the delay in publication of Esperite’s 2018 annual report as announced on 30 April 2019. The listing measure will be effective as from 20 May 2019.
ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - email@example.com.
This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).